Piramal Pharma Ltd. (PPLPHARMA) Share Price Surges 4.86% Today

Piramal Pharma Ltd. Share Price rises 4.86% to Rs 189.95, marking a significant gain in the large-cap category.

Piramal Pharma Ltd. Share Price has experienced a notable increase today, rising by 4.86% to reach Rs 189.95. This surge in price places the company among the top gainers in the large-cap category, where it has surpassed the qualifying threshold of 3%. With a market capitalisation of Rs 24,117.37 crore, Piramal Pharma Ltd. has captured the attention of investors and analysts alike. The substantial price rise is a significant event, highlighting the company's performance in the market today.

Today's price movement is noteworthy as it reflects a strong market response, although the specific catalyst behind this surge is not established by the available data. The increase in share price is accompanied by a high trading volume, indicating robust investor interest. As the company operates within the healthcare sector, this price action may also be influenced by broader sector trends and investor sentiment.

Piramal Pharma Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 189.95
Previous Close	Rs 181.15
Today's Change	+Rs 8.8 (+4.86%)
Day Open	Rs 181
Day High	Rs 192.6
Day Low	Rs 180.65
Current Volume (BSE)	35,43,262
BSE Traded Volume	35,43,262
NSE Traded Volume	1,02,50,864
Combined NSE + BSE Volume	1,37,94,126
Turnover	Rs 67.3 crore
Market Capitalisation	Rs 24,117.37 crore
Market Cap Category	Large Cap
Qualifying Threshold Cleared	3%

Today's trading session saw Piramal Pharma Ltd. open at Rs 181, slightly above the previous close of Rs 181.15. The stock reached a high of Rs 192.6 and a low of Rs 180.65, demonstrating a range of price movements throughout the day. The turnover for the day was Rs 67.3 crore, reflecting substantial trading activity.

The total volume of shares traded was 13,794,126, with the majority of trading occurring on the NSE. This high volume suggests significant investor participation, which aligns with the stock's price rise. As a large-cap stock, Piramal Pharma Ltd. needed to clear a 3% threshold to qualify as a top gainer, and today's 4.86% increase comfortably surpasses this benchmark.

The price action today indicates strong investor interest and market activity, positioning Piramal Pharma Ltd. as a key player in the healthcare sector. The stock's performance today may attract further attention from investors seeking opportunities in the sector.

Piramal Pharma Ltd. Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 24,117.37 crore
P/E Ratio	31.07x
P/B Ratio	2.36x
ROE	29.2%
ROCE	27.13%

Piramal Pharma Ltd. was valued at a P/E ratio of 31.07x, a P/B ratio of 2.36x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 29.2% and ROCE of 27.13%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Piramal Pharma Ltd. is currently valued at a market capitalisation of Rs 24,117.37 crore, with a price-to-earnings (P/E) ratio of 31.07 and a price-to-book (P/B) ratio of 2.36. The company's return on equity (ROE) stands at 29.2%, while the return on capital employed (ROCE) is 27.13%, indicating strong profitability and efficient capital utilisation.

The company's P/E ratio is aligned with the sector median of 20.79, suggesting a fair valuation relative to its peers. The P/B ratio of 2.36 is slightly above the sector median of 1.89, indicating a higher valuation in terms of book value. However, the company's strong ROE and ROCE figures demonstrate its ability to generate returns, which may justify the higher valuation multiples.

In terms of profitability, Piramal Pharma Ltd. exhibits robust financial metrics, which could be a factor in attracting investor interest. The company's performance in the healthcare sector, combined with its financial strength, positions it as a competitive player in the market.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Companies in Benchmark	203
Company P/E Ratio	31.07x
Benchmark Median P/E	20.79x
Benchmark Average P/E	67.01x
Benchmark P/E Range	0x to 3,482.29x
Companies with P/E Data	203
Company P/B Ratio	2.36x
Benchmark Median P/B	1.89x
Company ROE	29.2%
Benchmark Median ROE	10.69%
Company ROCE	27.13%
Benchmark Median ROCE	13.12%
Company Market Capitalisation	Rs 24,117.37 crore
Benchmark Median Market Cap	Rs 130.49 crore

Piramal Pharma Ltd. (PPLPHARMA) is classified under sector: Healthcare. The numerical benchmark uses 203 same sector companies from the supplied master-data set.

Piramal Pharma Ltd. (PPLPHARMA) has a P/E ratio of 31.07x, which is above the benchmark median of 20.79x, a difference of +49.45%. The benchmark contains 203 companies with P/E data, ranging from 0x to 3,482.29x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Piramal Pharma Ltd. (PPLPHARMA) has a ROE of 29.2%, which is above the benchmark median of 10.69%, a difference of +173.15%. Piramal Pharma Ltd. (PPLPHARMA) has a ROCE of 27.13%, which is above the benchmark median of 13.12%, a difference of +106.78%.

Track today's top gainers through the Univest top gainers screener. The peer table below provides the company-level comparison.

Piramal Pharma Ltd. operates within the healthcare sector, which comprises 203 companies in the benchmark scope. The sector's P/E median is 20.79, with an average of 67.01, indicating a wide range of valuations within the industry. The company's P/E ratio of 31.07 places it above the sector median, suggesting a relatively higher valuation.

The sector's P/B median is 1.89, with Piramal Pharma Ltd.'s P/B ratio at 2.36, indicating a premium valuation compared to the sector. The company's ROE of 29.2% and ROCE of 27.13% are significantly above the sector medians of 10.69% and 13.12%, respectively, highlighting its superior profitability and efficiency.

With a market capitalisation of Rs 24,117.37 crore, Piramal Pharma Ltd. is a major player in the healthcare sector. The company's strong financial performance and market position make it an attractive option for investors seeking exposure to the healthcare industry.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Morepen Laboratories Ltd.	MOREPENLAB	2,947.44	31.07	2.36	29.2	27.13
Dishman Carbogen Amcis Ltd.	DCAL	2,885.59	29.61	0.43	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,881.37	42.78	8.71	28.21	26.35
Beta Drugs Ltd.	BETA	2,567.04	61.88	8.27	18.65	22.17
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,425.38	34.6	7	-2.6	16.92

Piramal Pharma Ltd. (PPLPHARMA) has a P/E ratio of 31.07x compared with the displayed peer median of 34.6x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 29.2% compares with a peer median of 18.65% across the companies shown in the table. ROCE stood at 27.13% versus the displayed peer median of 22.17%, providing a capital-efficiency comparison. Piramal Pharma Ltd. (PPLPHARMA) has a market capitalisation of Rs 24,117.37 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

When compared to its peers, Piramal Pharma Ltd. demonstrates competitive financial metrics. Morepen Laboratories Ltd., with a market cap of Rs 2,947.44 crore, shares the same P/E and P/B ratios as Piramal Pharma Ltd., indicating similar valuation levels. Kwality Pharmaceuticals Ltd., with a higher P/E of 42.78, suggests a more expensive valuation relative to earnings.

In terms of profitability, Piramal Pharma Ltd.'s ROE of 29.2% and ROCE of 27.13% are among the highest in the peer group, showcasing its strong financial performance. This positions the company favorably against competitors such as Dishman Carbogen Amcis Ltd. and Beta Drugs Ltd., which have lower profitability metrics.

Why Investors Are Watching Piramal Pharma Ltd.

Investors are closely monitoring Piramal Pharma Ltd. due to its significant price rise and strong financial performance. The company's position in the healthcare sector, combined with its robust profitability metrics, makes it an attractive investment option.

• Price Action: 4.86% rise to Rs 189.95
• Technical Position: Strong market interest
• Fundamental Context: High ROE and ROCE
• Sector Positioning: Competitive in healthcare

Investors should continue to observe Piramal Pharma Ltd.'s market movements and financial performance to identify potential opportunities and risks in the evolving healthcare sector.

About Piramal Pharma Ltd.

Piramal Pharma Ltd. is a prominent player in the healthcare sector, focusing on the development and manufacturing of pharmaceutical products. The company operates in various segments, including pharmaceuticals and healthcare solutions, catering to a diverse range of medical needs.

With a strong presence in the industry, Piramal Pharma Ltd. leverages its expertise to deliver high-quality healthcare solutions. The company's commitment to innovation and excellence has positioned it as a leader in the market, offering a wide array of products and services to meet the demands of the healthcare sector.

Track Piramal Pharma Ltd. Share Price on Univest

Use Piramal Pharma Ltd. (PPLPHARMA) live share-price page, Univest top gainers screener, Univest market blogs to review live stock data, top gainers lists and related market analysis.

Investors and analysts can track Piramal Pharma Ltd. Share Price on Univest to stay updated on live market movements, technical indicators, and fundamental ratios. Univest provides comprehensive insights into the company's shareholding pattern, 52-week levels, and market trends, enabling informed investment decisions.

Frequently Asked Questions

What is the current share price of Piramal Pharma Ltd.?

Ans. The current share price of Piramal Pharma Ltd. is Rs 189.95, reflecting a 4.86% increase from the previous close of Rs 181.15. The stock moved 4.86% during the session. The intraday range extended from Rs 180.65 to Rs 192.6.

How much did Piramal Pharma Ltd. share price rise today?

Ans. Piramal Pharma Ltd. share price rose by 4.86% today, marking a significant gain in the large-cap category. The stock moved 4.86% during the session. The intraday range extended from Rs 180.65 to Rs 192.6.

What is the market capitalisation of Piramal Pharma Ltd.?

Ans. Piramal Pharma Ltd. has a market capitalisation of Rs 24,117.37 crore, positioning it as a major player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 31.07x.

What is the P/E ratio of Piramal Pharma Ltd.?

Ans. The P/E ratio of Piramal Pharma Ltd. is 31.07, which is above the sector median of 20.79, indicating a higher valuation. The company trades at a P/E ratio of 31.07x.

How does Piramal Pharma Ltd.'s ROE compare to the sector?

Ans. Piramal Pharma Ltd.'s ROE of 29.2% is significantly above the sector median of 10.69%, showcasing strong profitability. ROE stands at 29.2%. ROCE stands at 27.13%. The relevant peer median ROE is 10.69%.

How does Piramal Pharma Ltd.'s P/B ratio compare to the sector?

Ans. Piramal Pharma Ltd.'s P/B ratio of 2.36 is above the sector median of 1.89, suggesting a premium valuation. The company trades at a P/E ratio of 31.07x. Its P/B ratio is 2.36x.

What is the ROCE of Piramal Pharma Ltd.?

Ans. The ROCE of Piramal Pharma Ltd. is 27.13%, which is significantly above the sector median of 13.12%, indicating efficient capital utilisation. ROE stands at 29.2%. ROCE stands at 27.13%. The relevant peer median ROE is 10.69%.

Who are the peers of Piramal Pharma Ltd.?

Ans. Peers of Piramal Pharma Ltd. include Morepen Laboratories Ltd., Dishman Carbogen Amcis Ltd., and Kwality Pharmaceuticals Ltd., among others. Comparable listed companies include Morepen Laboratories Ltd., Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd.